Document Detail

Aflibercept for Intravitreal Injection : In Neovascular Age-Related Macular Degeneration.
MedLine Citation:
PMID:  23038609     Owner:  NLM     Status:  Publisher    
Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) family members VEGF-A, VEGF-B and placental growth factor, thereby preventing these ligands from binding to, and activating, their cognate receptors. The efficacy of intravitreal aflibercept in the treatment of wet (neovascular) age-related macular degeneration has been compared with that of intravitreal ranibizumab, the current gold standard for this indication, in two pivotal phase III studies of virtually identical design (VIEW 1 and 2). In both trials, the recommended regimen of aflibercept [2 mg every second month (after three initial monthly doses)] was shown to be noninferior to the recommended regimen of ranibizumab (0.5 mg every month) in terms of the primary endpoint of the proportion of patients who maintained their vision after 1 year of treatment; similar results were seen when monthly dosing with aflibercept (0.5 or 2 mg) was compared with ranibizumab. Over a period of 96 weeks in the VIEW studies, patients receiving the recommended regimen of aflibercept during the first year followed by modified quarterly treatment during the second year had a similar visual acuity gain to those receiving the recommended regimen of ranibizumab during first year followed by modified quarterly treatment during the second year, but on average required five fewer injections. Aflibercept was generally well tolerated in the VIEW studies; the ocular and non-ocular adverse event profile of the drug was similar to that of ranibizumab.
James E Frampton
Related Documents :
23076459 - Argon plasma coagulation is safe and effective for treating smaller gastric lesions wit...
23226229 - The impact of expanded testing for multidrug resistant tuberculosis using genotype [cor...
23803709 - European leukemianet recommendations for the management of chronic myeloid leukemia: 2013.
23283179 - Evaluation of different combined regimens in the treatment of cholinergic urticaria.
11349779 - Sensorineural hearing loss and otosclerosis: a clinical and radiologic survey of 437 ca...
22932839 - Radiofrequency ablation of the great saphenous vein with the closurefast™ procedure: ...
17899009 - Computer-assisted total knee arthroplasty versus the conventional technique: how precis...
9262079 - Re-do cardiac surgery in patients over 70 years old.
10738049 - Amiodarone to prevent recurrence of atrial fibrillation. canadian trial of atrial fibri...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-5
Journal Detail:
Title:  Drugs & aging     Volume:  -     ISSN:  1170-229X     ISO Abbreviation:  Drugs Aging     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9102074     Medline TA:  Drugs Aging     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diagnosing and managing postherpetic neuralgia.
Next Document:  Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) : A Guide to Its Use in Older Ad...